Close Menu

Just Getting By

At Genetic Future, Daniel MacArthur points out a press release from Decode Genetics on their second quarter financials. According to the release, the company brought in $3.5 million for 2009 as compared to $9.0 million for the same quarter last year. "The goal of our strategic review is to recast deCODE as a diagnostics company positioned to lead in this growing new market," CEO Kari Stefansson says in the statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.